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Abstract
Background: The measurement of carbohydrate anti-
gen 19-9 (CA 19-9) is recommended for the diagnosis
and follow-up of pancreatic cancer. However,
increased CA 19-9 has also been reported in patients
with various benign diseases of the lung. We aimed
to elucidate the pulmonary radiographic abnormali-
ties and laboratory results associated with increased
concentrations of CA 19-9.
Methods: This study was performed using a case-con-
trolled design. Cases included all participants in a
cancer screening program who had an increased CA
19-9 concentration ()37 U/mL), but without a diag-
nosis of malignancy. Age- and sex-matched partici-
pants with normal CA 19-9 levels were enrolled as
controls. Laboratory results and radiographic features
were compared.
Results: In total, 119 participants with increased CA
19-9 concentrations and 476 controls were included.
A higher erythrocyte sedimentation rate (ESR) wadjust-
ed odd ratio (aOR), 1.03; 95% confidence interval (CI),
1.01–1.05x, higher hemoglobin A1c (HbA1c) (aOR, 1.28;
95% CI, 1.05–1.56), bronchiectasis (aOR, 2.48; 95% CI,
1.22–5.02), bronchiolitis (aOR, 3.93; 95% CI, 1.88–
8.22), emphysema (aOR, 2.67; 95% CI, 1.32–5.40), and
interstitial fibrosis (aOR, 10.62; 95% CI, 2.03–55.44)
were independent factors for increased CA 19-9.
Conclusions: CA 19-9 concentrations, as well as
increased ESR and HbA1c, can be increased in patients
with various lung abnormalities.
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Introduction
Carbohydrate antigen 19-9 (CA 19-9) is the sialylated
Lewis (Le)a blood group antigen. Individuals with an
Lea–b– phenotype, lacking the Lewis antigen glycosyl-
tranferase, are unable to synthesize CA 19-9 (1). Orig-
inally recognized as a tumor-associated antigen, it
was defined using monoclonal antibody (1116 NS 19-
9) produced from a hybridoma prepared from mouse
spleen following immunization with human colorectal
carcinoma cell line (2, 3). The usefulness of serum CA
19-9 concentrations for diagnosis of pancreatic cancer
is well recognized (4, 5).
Increased concentrations of serum CA 19-9 have
also been reported in other types of malignant, as
well as in benign diseases. In particular, there are
occasional reports of increased CA 19-9 in several
benign lung diseases, including cystic fibrosis (6),
idiopathic pulmonary fibrosis (7), pulmonary seques-
tration (8), and Mycobacterium intracellular complex
lung diseases (9). However, few studies have syste-
matically evaluated the relationship between
increased CA 19-9 and non-malignant lung diseases.
We attempted to elucidate the pulmonary radiograph-
ic abnormalities and laboratory results associated
with an increased CA 19-9.
Materials and methods
Study design and enrollees
This study was performed using a case-controlled design.
Cases and controls were selected individuals participating in
a cancer screening program from 1 January 2004 to 31
December 2006 at Healthcare System Gangnam Center, a
clinic for comprehensive cancer screening affiliated with
Seoul National University Hospital. Participation in the can-
cer screening program is voluntarily and at each individuals
own expense. Cases included every patient showing an
increased CA 19-9 concentration ()37 U/mL), but without a
diagnosis of malignancy. We included four times as many
age- and sex-matched participants with normal CA 19-9 con-
centration as controls. The protocol for this study was
approved by the Ethics Review Committee of the Seoul
National University Hospital.
Protocols for the cancer screening program
Physical examinations Physical examinations, including
height and weight measurements, were performed by
board-certified physicians.
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Figure 1 Serum concentrations of CA 19-9 among 130
patients with increased values (CA 19-9 )37 U/mL).
Laboratory tests Laboratory tests consisted of the follow-
ing: leukocyte count including differential counts, hemato-
crit, hemoglobin, platelet count, total cholesterol, total
protein, albumin, total and direct bilirubin, alkaline phospha-
tase, aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), blood urea nitrogen, creatinine, electrolytes,
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), prothrombin time, activated partial thromboplastin
time, hemoglobin A1c (HbA1c), Venereal Disease Research
Laboratory (VDRL) test, hepatitis B surface antigen, anti-hep-
atitis B virus antibody, anti-hepatitis C virus antibody, anti-
HIV antibody, triiodothyronine, free thyroxine, thyroid
stimulating hormone, urinalysis, and stool occult blood.
Radiological examinations Low-dose computerized tomo-
graphy of the chest (LDCT), mammography with andwithout
breast sonography in women, abdominal sonography or
abdominal CT, and thyroid sonography were performed.
LDCT of the chest was performed using a 16-detector scan-
ner (SOMATOM Sensation 16, Siemens Medical Systems,
Munich, Germany) with the following settings: 0.75 mm col-
limation=16 channels; 5-mm thickness reconstruction with
5-mm intervals; pitch (ratio of travel per rotation to total
beam width), 1.0; 120 kVp; and 40 (120 mA/0.33 s) mAs.
Lesion characterization, if necessary, was accomplished by
obtaining 1 mm thin-section CT reconstruction images.
Other evaluations Pulmonary function tests, including
forced expiratory volume at 1 s (FEV1) and forced vital capac-
ity (FVC), esophago-gastroduodenoscopy, and colonoscopy
were performed.
Measurement of tumor markers Serum CA 19-9 concentra-
tions were measured with an enzyme immunoradiometric
assay kit (TFB, Tokyo, Japan). CA 19-9 concentrations )37
U/mL were considered increased (10). Serum carcinoem-
bryonic antigen (CEA; RADIM, Rome, Italy), a-fetoprotein
(AFP; Immunotech a.s., Prague, Czech Republic), carbohy-
drate antigen 125 (CA 125; TFB, Tokyo, Japan), and prostate-
specific antigen (PSA; Cis Bio International, Gif-sur-Yvette,
France) were also measured using enzyme immunoradio-
metric assays. Measurements were performed by techni-
cians blinded to the clinical information about the samples.
Definition of pulmonary radiographic abnormalities
Pulmonary lesions on LDCT were evaluated by a board-
certified chest radiologist blinded to the CA 19-9 level.
• Emphysema was defined by the presence of focal areas
or regions of low attenuation without visible walls (11).
• Interstitial fibrosis was diagnosed if LDCT showed bilat-
eral basilar subpleural reticulation, usually accompanied
by traction bronchiectasis and architectural distortion and
honeycomb cysts (12).
• Bronchiectasis was diagnosed based on findings that
included dilatation of an airway lumen, rendering it more
than 1.5 times the width of a nearby vessel; lack of taper-
ing of an airway toward the periphery; varicose constric-
tions along airways; and ballooned cysts at the end of a
bronchus (13).
• Bronchiolitis was diagnosed when lesions such as the
tree-in-bud pattern, centrilobular nodules, and bronchio-
lar wall thickening were observed (11).
• Sequelae of pulmonary tuberculosis (TB) were identified
by LDCT observations of fibrotic bands, small calcified
nodules, or bronchiectasis in the upper lobes (14).
Statistical analysis
The x2-test for comparison of categorical variables and the
t-test for comparison of continuous variables between cases
and controls were applied. The variables analyzed included
body mass index, comorbidities, smoking status, leukocyte
count, segmented neutrophil count, eosinophil count,
hematocrit, ESR, CRP, total bilirubin, AST, ALT, HbA1c, cre-
atinine, CEA, AFP, CA 125, PSA, FEV1, FVC, and various
radiographic lung abnormalities. To identify predictors for
increased CA 19-9, multiple logistic regression models were
constructed by including any variables with a p-0.10. Back-
ward elimination was used to select the variables to bemain-
tained in the final model. CEA, AFP, CA 125, and PSA were
excluded from the final model since they could not explain
the increase of CA 19-9. A Hosmer-Lemeshow Goodness of
Fit (GOF) test was performed to confirm the fitness of the
final model. Statistical significance was considered if
p-0.05. All statistical analyses were performed using SPSS
(Version 12.0, Chicago, IL, USA).
Results
Baseline characteristics of enrolled patients
We evaluated 11,096 participants; 130 of which had a
CA 19-9 concentration )37 U/mL (Figure 1). Of these
130 patients, 11 were excluded due to malignancy:
five patients with pancreatic cancer; two with hepa-
tocellular carcinoma; one with lung cancer; one with
colon cancer; one with papillary thyroid carcinoma;
and one patient with malignant teratoma. Four times
as many age- and sex-matched participants with nor-
mal CA 19-9 concentrations were included as con-
trols. Thus, a total of 119 participants with increased
CA 19-9 and 476 participants with normal CA 19-9
concentrations were included in the analysis. Body
mass index, smoking status, and comorbidities were
not different between the two groups. However, dia-
betes mellitus was more common in the group of
patients who had CA 19-9 )37 U/mL (22.7% vs.
11.8%, ps0.002). The leukocyte count, neutrophil
count, ESR, HbA1c, CEA, and CA 125 were higher in
participants with increased CA 19-9 compared with
controls (Table 1).
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Table 1 Comparison of baseline characteristics between participants with increased and normal CA 19-9 concentrations.
Patients with Patients with p-Value
increased CA 19-9 normal CA 19-9
()37 U/mL) (0–37 U/mL)
(ns119) (ns476)
Age, median (range), years 56 (33–83) 56 (32–84) 0.98
Sex, female 64 (53.8%) 256 (53.8%) 1.00
Body mass index, kg/m2 22.9"3.0 23.3"2.8 0.19
Current smoker 21 (20.6%) 77 (17.2%) 0.42
Comorbidities
Hypertension 44 (37.3%) 143 (30.4%) 0.15
Diabetes mellitus 27 (22.7%) 56 (11.8%) 0.002
Dyslipidemia 42 (35.3%) 134 (28.2%) 0.13
Chronic liver disease 6 (5.0%) 41 (8.6%) 0.20
Laboratory findings
White blood cell count, =109/L 6.26"1.98 5.63"1.66 0.002
Segmented neutrophil count, =109/L 3.76"1.73 3.25"1.42 0.004
Eosinophil count, =109/L 0.18"0.21 0.15"0.14 0.17
Hematocrit, % 42.5"4.7 42.7"4.0 0.65
Erythrocyte sedimentation rate, mm/h 13"17 8"8 0.002
C-reactive protein, g/L 0.004"0.20 0.001"0.003 0.15
Total bilirubin, mmol/L 17.45"8.27 18.76"9.48 0.17
AST, U/L 30"44 26"11 0.27
ALT, U/L 32"74 25"16 0.36
Creatinine, mmol/L 87.87"17.38 88.77"16.08 0.59
Hemoglobin A1c, % 6.1"1.4 5.8"0.8 0.02
Pulmonary function tests
Forced vital capacity, L 3.28"0.78 3.36"0.74 0.31
Forced expiratory volume in 1 s, L 2.59"0.65 2.66"0.60 0.26
FEV1/FVC, % 79"8 80"7 0.76
Tumor markers
CA 19-9, U/mL 78"107 10"7 -0.001
CEA, mg/L 2.3"1.6 1.6"0.9 -0.001
AFP, mg/L 7"22 5"4 0.23
PSA, mg/L 1.6"2.1 1.4"1.2 0.38
CA 125, U/mL 21"26 10"7 0.002
AST, asparatate aminotransferase; ALT, alanine aminotransferase; ESR, erythrocyte sedimentation rate; CA 19-9, carbohydrate
antigen 19-9; AFP, a-fetoprotein; CEA, carcinoembryonic antigen; PSA, prostate-specific antigen; CA 125, carbohydrate antigen
125.
Table 2 Comparison of pulmonary parenchymal abnormalities based on low-dose chest CT between participants with
increased and normal CA 19-9 concentrations.
Patients with Patients with p-Value
increased CA 19-9 normal CA 19-9
()37 U/mL) (0–37 U/mL)
(ns119) (ns476)
Absence of abnormal lesion 51 (42.9%) 348 (73.1%) -0.001
Presence of abnormal lesiona 68 (57.1%) 128 (26.9%)
Sequelae of pulmonary TB 26 (21.8%) 71 (14.9%) 0.07
Bronchiectasis 21 (17.6%) 26 (5.5%) -0.001
Bronchiolitis 20 (16.8%) 22 (4.6%) -0.001
Emphysema 18 (15.1%) 27 (5.7%) -0.001
Interstitial fibrosis 6 (5.0%) 2 (0.4%) 0.001
aIf two or more characteristics were present in one patient, they were counted separately. TB, tuberculosis.
Prevalence of pulmonary radiographic
abnormalities
The prevalence of pulmonary radiographic abnormal-
ities was higher in participants with increased CA 19-
9 concentrations compared to those with normal
concentrations (57.1% vs. 26.9%, p-0.001) and
sequelae of pulmonary TB was the most frequent
abnormal findings (21.8% and 14.9%, respectively).
All categories of pulmonary abnormalities, except
sequelae of pulmonary TB, were more common in
participants with increased CA 19-9 concentrations
(Table 2).
Characteristics associated with increased CA 19-9
ESR, HbA1c, cholecystitis, sequelae of TB, bronchiec-
tasis, bronichiolitis, emphysema, and interstitial fibro-
sis were included as variables in the final multiple
logistic regression model. Among these variables,
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Table 3 Laboratory and radiographic characteristics associated with increased CA 19-9 (multivariable analysis)a.
Patients with Patients with p-Value OR 95% CI
increased CA 19-9 level normal CA 19-9
()37 U/mL) (0–37 U/mL)
(ns119) (ns476)
ESR, mm/hb 13"17 8"8 0.005 1.03 1.01–1.05
HbA1c, %c 6.1"1.4 5.8"0.8 0.02 1.28 1.05–1.56
Sequelae of pulmonary TB 26 (21.8%) 71 (14.9%) 0.13 1.55 0.88–2.71
Bronchiectasis 21 (17.6%) 26 (5.5%) 0.01 2.48 1.22–5.02
Bronchiolitis 20 (16.8%) 22 (4.6%) -0.001 3.93 1.88–8.22
Emphysema 18 (15.1%) 27 (5.7%) 0.006 2.67 1.32–5.40
Interstitial fibrosis 6 (5.0%) 2 (0.4%) 0.005 10.62 2.03–55.44
aHosmer-Lemeshow Goodness of Fit: p-value 0.700; b(xq1 mm/h vs. x mm/h); c(xq1% vs. x%); ESR, erythrocyte sedimentation
rate; HbA1c, hemoglobin A1c; TB, tuberculosis.
ESR wadjusted odd ratio (aOR), 1.03; 95% confidence
interval (CI), 1.01–1.05x, HbA1c (aOR, 1.28; 95% CI,
1.05–1.56), bronchiectasis (aOR, 2.48; 95% CI, 1.22–
5.02), bronchiolitis (aOR, 3.93; 95% CI, 1.88–8.22),
emphysema (aOR, 2.67; 95% CI, 1.32–5.40), and inter-
stitial fibrosis (aOR, 10.62; 95% CI, 2.03–55.44) were
independent factors for increased CA 19-9. The fitness
of this model was confirmed with the Hosmer-Lemes-
how GOF test (ps0.700) (Table 3).
Follow-up measurements of CA 19-9 concentrations
and results of subsequent cancer screenings
Follow-up measurements of CA 19-9 concentrations
were performed in 88 of 119 patients (73.9%) after
median of 100 days (range: 8–980 days) following the
initial measurements. Of these 88 patients, concentra-
tions of CA 19-9 decreased to within the normal range
in 58 (65.9%).
Of the 119 patients with increased CA 19-9 concen-
trations, cancer screening was repeated in 85 patients
(71.4%) at 30 months (range: 6–60 months) after initial
screening. Only one patient was diagnosed with can-
cer (hepatocellular carcinoma).
Discussion
It is recommended that CA 19-9 be measured every
1–3 months in patients with locally advanced or meta-
static pancreatic cancer who are undergoing treat-
ment (15). However, CA 19-9 may be increased in oth-
er malignancies such as ovarian cancer, colon cancer,
and gastric cancer (16). In addition, CA 19-9 increases
have been reported in various benign conditions such
as Hashimoto’s thyroiditis (16), benign biliopancreatic
diseases (17), and several lung diseases (6–9). In the
present study, 11 (8.5%) out of 130 participants with
increased CA 19-9 had malignancy; only five of which
had pancreatic cancer. This observation suggests that
the specificity of increased CA 19-9 for the presence
of pancreatic cancer is very low. In addition, the tran-
sient elevations in CA 19-9 that we observed in two-
thirds of patients weakens the rationale of using CA
19-9 for cancer screening.
In addition, 68 (57.1%) of the 119 participants with
increased CA 19-9 concentrations had various pul-
monary radiographic abnormalities but no malignant
diseases. In a logistic regression model, an increased
ESR and HbA1c, and the presence of bronchiectasis,
bronchiolitis, emphysema, and interstitial fibrosis
were associated with higher concentration of CA 19-9.
The mechanism responsible for increased CA 19-9
in pulmonary abnormalities is yet to be defined. How-
ever, the presence of inflammatory processes in bron-
chiectasis, bronchiolitis, interstitial fibrosis, and
emphysema could help mediate higher CA 19-9 con-
centrations. In fact, other benign diseases associated
with increased CA 19-9 include pyogenic liver abscess
(18), diverticulitis (19), lumbar abscess (20), pelvic
inflammatory disease (21), Hashimoto’s thyroiditis
(16), and connective tissue diseases including rheu-
matoid arthritis (22). These observations suggest that
increased CA 19-9 is possibly associated with inflam-
mation. Our finding that an increased ESR was asso-
ciated with an increased CA 19-9 concentrations
further supports this idea. Furthermore, CA 19-9 along
with other tumor markers was recently proposed as
an adhesion molecule in synovial inflammation (23).
Some reports indicate increased CA 19-9 in patients
with diabetes (24, 25). In addition, a corresponding
change in CA 19-9 with HbA1c in patients with diabe-
tes has also been reported (26). This proposed rela-
tionship between HbA1c and CA 19-9 is supported by
our study. Given that the inflammatory processes are
important in etiology (27) as well as in complications
of diabetes (28), these findings could be mediated
through inflammation.
To properly appreciate these results, we note some
limitations of our study. First, the diagnoses of pul-
monary abnormalities were based on LDCT findings
without consideration of clinical symptoms and pul-
monary function. Differences might have been iden-
tified if clinical diagnoses of various lung diseases
were used along with radiographic features. Second,
the study population did not reflect the general
population. The people participating in the cancer
screening program tended to be wealthier and more
concerned about their health. Prospective studies
involving people with diverse economic circumstan-
ces and including detailed clinical findings and pul-
monary functions should be undertaken in the future.
In conclusion, increased ESR and HbA1c, in addition
to various radiographic lung abnormalities, constitute
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the majority of benign conditions associated with an
increased serum CA 19-9 concentration. Clinicians
should interpret CA 19-9 concentrations in patients
with these clinical conditions with caution.
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